Results 131 to 140 of about 3,715,425 (177)

[Immunotropic activity of a potential antiparkinson agent himantane].

Eksperimental'naia i klinicheskaia farmakologiia, 2001
N-(Adamant-2-yl) hexamethyleneimine hydrochloride (A-7, himantane), a new potential antiparkinsonian drug belonging to the class of aminoadamantyl derivatives, exhibits pronounced immunomodulant activity in a therapeutic dose of 10 mg/kg. A single intraperitoneal injection of himantane stimulated a high B-lymphocyte activity in mice over a period of 21
G I, Nezhinskaia, E A, Val'dman, P G, Nazarov, T A, Voronina   +3 more
openaire   +2 more sources

REVERSAL OF SOME THERAPEUTIC EFFECTS OF AN ANTIPSYCHOTIC AGENT BY AN ANTIPARKINSONISM DRUG

The Journal of Nervous and Mental Disease, 1973
Data are presented from a multidimensional, longitudinal study in 10 acute schizophrenics which indicate that the addition of benztropine to haloperidol reversed the course of some of the therapeutic changes. The nontherapeutic interaction was selective involving what may be called social avoidance behavior but not the cognitive integrative ...
M M, Singh, J M, Smith
openaire   +2 more sources

Metabolism of antiparkinson agent dopazinol by rat liver microsomes.

Drug Metabolism and Disposition, 1990
Metabolism of dopazinol (DZ) by liver microsomes from control and phenobarbital- and 3-methylcholanthrene-treated rats has been investigated. Liver microsomes from control and treated rats metabolized DZ to N-despropyl-DZ (39-53% of total metabolites); 8-hydroxy-DZ, a catechol metabolite (32-39%); and 5- or 6-hydroxy-DZ (12-20%).
K P, Vyas, P H, Kari, H G, Ramjit, S M, Pitzenberger, M, Hichens   +4 more
openaire   +2 more sources

Novel isoxazole derivatives as potential antiparkinson agents: synthesis, evaluation of monoamine oxidase inhibitory activity and docking studies

Medicinal Chemistry Research, 2019
N. Agrawal, P. Mishra
semanticscholar   +2 more sources

[Phenibut potentiation of the therapeutic action of antiparkinson agents].

Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1986
It was observed in experiments on mice that the central action of phenibut (beta-phenyl-gamma-aminobutyric acid) diminished after destruction of brain dopaminergic neurons by 6-hydroxydopamine and after pretreatment with the dopamine receptor blocker haloperidol which suggests the dopaminergic component in the action of phenibut.
Iu V, Gol'dblat, I P, Lapin
openaire   +1 more source

Potential of Cellular and Animal Models Based on a Prion-Like Propagation of α-Synuclein for Assessing Antiparkinson Agents

Molecular Neurobiology, 2015
Hiroyasu Sato, T. Kato, S. Arawaka
semanticscholar   +1 more source

CONTROLLED STUDIES OF ANTIPARKINSONISM AGENTS IN THE TREATMENT OF DRUG‐INDUCED EXTRAPYRAMIDAL SYMPTOMS

Acta Psychiatrica Scandinavica, 1970
SUMMARYA series of four experiments designed to assess the effect of antiparkin‐sonism drugs on phenothiazine produced parkinsonism are described. It was difficult to distinguish the effects of the active drug from placebo when intravenous injections were employed, but using handwriting as an indication it was possible to distinguish the oral ...
openaire   +2 more sources

Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes

Journal of Pharmacology and Experimental Therapeutics, 2002
M. Millan, L. Maiofiss, D. Cussac, V. Audinot, J. Boutin, A. Newman-Tancredi   +5 more
semanticscholar   +1 more source

Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor Subtypes

Journal of Pharmacology and Experimental Therapeutics, 2002
A. Newman-Tancredi, D. Cussac, Y. Quentric, M. Touzard, L. Verrièle, N. Carpentier, M. Millan   +6 more
semanticscholar   +1 more source

Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. II. Agonist and Antagonist Properties at Subtypes of Dopamine D2-Like Receptor and α1/α2-Adrenoceptor

Journal of Pharmacology and Experimental Therapeutics, 2002
A. Newman-Tancredi, D. Cussac, V. Audinot, J. Nicolas, Frédéric De Ceuninck, J. Boutin, M. Millan   +6 more
semanticscholar   +1 more source